Abstract: . . .  10:30 -10:40 a.m. Discussion 10:40 -11:05 a.m. Coffee Break Management of Venous Thromboembolism 11:05 -11:20 a.m. Venous Thromboembolism Historical Perspective ................................ Arthur A. Sasahara, M.D. 11:20 -11:25 a.m. Discussion 11:25 -11:55 a.m. Epidemiology of Venous Thromboembolism .......................................................... Mary Cushman, M.D. 11:55 -12:05 p.m. Discussion 12:05 -12:35 p.m. Diagnosis of Pulmonary Embolism .................................................... Henri Bounameaux, M.D. 12:35 -12:40 p.m. Discussion 12:40 - 1:10 p.m. Risk Stratification of Pulmonary Embolism .............................. Samuel Z. Goldhaber, M.D. 1:10 - 1:20 p.m. Discussion 1:20 - 2:20 p.m. Lunch 2:20 - 2:50 p.m. Prevention of Venous Thromboembolism Embolism .............................. Samuel Z. Goldhaber, M.D. 2:50 - 3:00 p.m. Discussion . . .
. . .  .......................................................... Mary Cushman, M.D. 11:55 -12:05 p.m. Discussion 12:05 -12:35 p.m. Diagnosis of Pulmonary Embolism .................................................... Henri Bounameaux, M.D. 12:35 -12:40 p.m. Discussion 12:40 - 1:10 p.m. Risk Stratification of Pulmonary Embolism .............................. Samuel Z. Goldhaber, M.D. 1:10 - 1:20 p.m. Discussion 1:20 - 2:20 p.m. Lunch 2:20 - 2:50 p.m. Prevention of Venous Thromboembolism Embolism .............................. Samuel Z. Goldhaber, M.D. 2:50 - 3:00 p.m. Discussion Miniupdates 3:00 - 3:15 p.m. Direct Thrombin Inhibitors: Bivalirudin, Lepirudin, Argatroban ...................... David J. Kuter, M.D. 3:15 - 3:20 p.m. Discussion 3:20 - 3:35 p.m. Injectable anti-Xa Agents: Fondaparinux, Idraparinux ...................................... James Bradner, M.D. 3:35 - 3:40 p.m. Discussion . . .
. . .  Lake City, Utah Stavros V. Konstantinides, Associate Professor of Medicine, Vice-Chairman, Department of Cardiology and Pulmonary Medicine, George August University of Goettingen, Goettingen, Germany Daniel I. Simon, Herman K. Hellerstein Professor of Medicine; Director, Case Cardiovascular Center, Case School of Medicine; Chief, Division of Cardiology, University Hospitals of Cleveland/Case School of Medicine Jeffrey Weitz, Director of the Experimental Thrombosis and Atherosclerosis (ETA) Programme, Director, Henderson Research Center, Hamilton, Ontario, Canada  . . .
--3000,3,500,2870,16030